THE ROLE OF CYTOCHROMES-P-450 IN CYCLOSPORINE METABOLISM

被引:79
作者
WATKINS, PB
机构
[1] Ann Arbor, Michigan
关键词
D O I
10.1016/0190-9622(90)70358-O
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
In most patients, the rate-limiting step in the elimination of cyclosporine from the body is its conversion to metabolites by cytochrome P-450 IIIA enzymes in the liver and, possibly, intestine. The significant differences found among patients in the daily dose of cyclosporine required to attain target blood levels has been attributed directly to corresponding interpatient differences in the catalytic activities of P-450 IIIA enzymes. Competitive inhibition or induction of P-450 IIIA activity appears to explain most of the clinically significant interactions of drugs with cyclosporine metabolism that have been reported, The critical importance of P-450 IIIA in the body's handling of cyclosporine has made it possible to identify potential drug interactions before they are reported. Future investigations in this field are likely to result in reduction in the cost and toxicity associated with cyclosporine therapy. © 1990, American Academy of Dermatology, Inc.. All rights reserved.
引用
收藏
页码:1301 / 1311
页数:11
相关论文
共 64 条
[1]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[2]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH ;
BEKEMEYER, WB .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (03) :565-568
[3]  
BOURBIGOT B, 1986, LANCET, V1, P1447
[4]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[5]  
CANTAROVICH M, 1987, CLIN NEPHROL, V28, P190
[6]   INTERACTION BETWEEN CYCLOSPORINE-A AND PHENOBARBITONE [J].
CARSTENSEN, H ;
JACOBSEN, N ;
DIEPERINK, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (05) :550-551
[7]  
COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197
[8]  
DANIELS NJ, 1984, LANCET, V2, P639
[9]   CYCLOSPORINE, LOW-DENSITY LIPOPROTEIN, AND CHOLESTEROL [J].
DEGROEN, PC .
MAYO CLINIC PROCEEDINGS, 1988, 63 (10) :1012-1021
[10]   PHARMACOKINETIC DRUG-INTERACTIONS WITH MACROLIDE ANTIBIOTICS [J].
DESCOTES, J ;
ANDRE, P ;
EVREUX, JC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 (06) :659-664